Non-Human Mammal Model Of Human Hematopoietic Cancer
OwnerIlya B. Leskov, Adam C. Drake +4inventors
InventorsIlya B. Leskov, Adam C. Drake, Maroun Khoury, Jianzhu Chen, Christian Pallasch, Michael Hemann
Life of this patent
Estimating the term…
Loading patent…
OwnerIlya B. Leskov, Adam C. Drake +4inventors
InventorsIlya B. Leskov, Adam C. Drake, Maroun Khoury, Jianzhu Chen, Christian Pallasch, Michael Hemann
Estimating the term…
The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
A method of producing a non-human mammal that is a model for a human hematopoietic cancer comprising
3-5. (canceled)
(canceled)
10-16. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
27-28. (canceled)
30-31. (canceled)
(canceled)
A method of producing a non-human mammal that is a model for a human hematopoietic cancer comprising
37-41. (canceled)
A method of producing a non-human mammal that is a model for a human hematopoietic cancer patient comprising introducing hematopoietic stem cells (HSCs) of the hematopoietic cancer patient into an immunodeficient non-human mammal and maintaining the non-human mammal under conditions in which the non-human mammal's blood cell lineages is reconstitute by the HSCs and the one or more oncogenes of the cancer patient are expressed in the mammal, thereby producing a non-human mammal that is a model for the hematopoietic cancer patient.
43-47. (canceled)
(canceled)
51-52. (canceled)
A method of treating leukemia in an individual in need thereof comprising simultaneously administering an effective amount of an anti-CD52 antibody and one or more chemotherapeutic agents to the individual.
Dependencies are inferred from the claim text.